BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chendi BH, Snyders CI, Tonby K, Jenum S, Kidd M, Walzl G, Chegou NN, Dyrhol-Riise AM. A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. Front Immunol 2021;12:608846. [PMID: 33732236 DOI: 10.3389/fimmu.2021.608846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Korotetskaya MV, Rubakova EI. Metabolic biological markers for diagnosing and monitoring the course of tuberculosis. Russian Journal of Infection and Immunity 2022;12:827-836. [DOI: 10.15789/2220-7619-mbm-1947] [Reference Citation Analysis]
2 Mutavhatsindi H, Du Bruyn E, Ruzive S, Howlett P, Sher A, Mayer-barber KD, Barber DL, Ntsekhe M, Wilkinson RJ, Riou C. Blood and site of disease inflammatory profiles differ in HIV-1-infected pericardial tuberculosis patients.. [DOI: 10.1101/2022.10.21.513232] [Reference Citation Analysis]
3 Chendi BH, Jooste T, Scriba TJ, Kidd M, Mendelsohn S, Tonby K, Walzl G, Dyrhol-Riise AM, Chegou NN. Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting. Infect Dis (Lond) 2022;:1-11. [PMID: 36214761 DOI: 10.1080/23744235.2022.2129779] [Reference Citation Analysis]
4 Ndiaye MDB, Ranaivomanana P, Rasoloharimanana T, Rasolofo V, Ratovoson R, Herindrainy P, Rakotonirina J, Schoenhals M, Hoffmann J, Rakotosamimanana N. Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment.. [DOI: 10.21203/rs.3.rs-1908408/v1] [Reference Citation Analysis]
5 Manyelo CM, Solomons RS, Snyders CI, Kidd M, Kooblal Y, Leukes VN, Claassen C, Roos K, Stanley K, Walzl G, Chegou NN; TBMBIOMARKERS study group. Validation of host cerebrospinal fluid protein biomarkers for early diagnosis of tuberculous meningitis in children: a replication and new biosignature discovery study. Biomarkers 2022;:1-29. [PMID: 35506251 DOI: 10.1080/1354750X.2022.2071991] [Reference Citation Analysis]
6 Sivakumaran D, Jenum S, Ritz C, Vaz M, Doherty TM, Grewal HMS. Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis? Front Immunol 2022;13:801616. [DOI: 10.3389/fimmu.2022.801616] [Reference Citation Analysis]
7 Jacobs R, Awoniyi DO, Baumann R, Stanley K, McAnda S, Kaempfer S, Malherbe ST, Singh M, Walzl G, Chegou NN; AE-TBC Consortium. Concurrent evaluation of cytokines improves the accuracy of antibodies against Mycobacterium tuberculosis antigens in the diagnosis of active tuberculosis. Tuberculosis (Edinb) 2022;133:102169. [PMID: 35121532 DOI: 10.1016/j.tube.2022.102169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Luo Y, Xue Y, Song H, Tang G, Liu W, Bai H, Yuan X, Tong S, Wang F, Cai Y, Sun Z. Machine learning based on routine laboratory indicators promoting the discrimination between active tuberculosis and latent tuberculosis infection. J Infect 2022:S0163-4453(21)00666-6. [PMID: 34995637 DOI: 10.1016/j.jinf.2021.12.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mann TN, Davis JH, Walzl G, Beltran CG, du Toit J, Lamberts RP, Chegou NN. Candidate Biomarkers to Distinguish Spinal Tuberculosis From Mechanical Back Pain in a Tuberculosis Endemic Setting. Front Immunol 2021;12:768040. [PMID: 34868023 DOI: 10.3389/fimmu.2021.768040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Luo Y, Xue Y, Tang G, Lin Q, Song H, Liu W, Yin B, Huang J, Wei W, Mao L, Wang F, Sun Z. Combination of HLA-DR on Mycobacterium tuberculosis-Specific Cells and Tuberculosis Antigen/Phytohemagglutinin Ratio for Discriminating Active Tuberculosis From Latent Tuberculosis Infection. Front Immunol 2021;12:761209. [PMID: 34858413 DOI: 10.3389/fimmu.2021.761209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chendi BH, Tveiten H, Snyders CI, Tonby K, Jenum S, Nielsen SD, Hove-Skovsgaard M, Walzl G, Chegou NN, Dyrhol-Riise AM. CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. J Infect 2021:S0163-4453(21)00379-0. [PMID: 34333033 DOI: 10.1016/j.jinf.2021.07.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Stefanescu S, Cocoș R, Turcu-Stiolica A, Shelby ES, Matei M, Subtirelu MS, Meca AD, Stanciulescu EC, Popescu SO, Biciusca V, Pisoschi CG. Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results. Pathogens 2021;10:789. [PMID: 34206598 DOI: 10.3390/pathogens10070789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]